附件: 热泵以欢迎机构投资者 疫情态安装团购物 E L R R R R R R 注:左七为公司董事会秘书张斌与调研人员合影留念。 ...

证券代码：002030 证券简称：达安基因 公告编号：2023-038 医疗器械名称：丙型肝炎病毒核酸测定试剂盒（PCR-荧光探针法），注册证 编号：国械注准 20233401279。有效期自批准之日起至 2028 年 9 月 4 日。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 特此公告。 广州达安基因股份有限公司 董 事 会 2023 年 9 月 6 日 广州达安基因股份有限公司 关于取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督 管理局颁发的医疗器械注册证一个，具体为： ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥536,218,449.35, a decrease of 91.97% compared to the same period last year[51]. - The net profit attributable to shareholders of the listed company was ¥402,755,388.71, down 88.80% year-on-year[51]. - The net profit after deducting non-recurring gains and losses was ¥102,897,120.82, a decline of 97.03% compared to the previous year[51]. - The net cash flow from operating activities was -¥38,382,493.67, a decrease of 102.25% compared to the same period last year[51]. - Basic earnings per share were ¥0.29, down 88.67% from ¥2.56 in the same period last year[51]. - Total assets at the end of the reporting period were ¥11,708,971,705.38, a decrease of 20.66% from the end of the previous year[51]. - The net assets attributable to shareholders of the listed company were ¥9,187,500,489.81, down 18.70% from the previous year[51]. - The weighted average return on net assets was 3.50%, a decrease of 36.95% compared to 40.45% in the same period last year[51]. - The company reported a total non-operating income of 299,858,267.89 CNY, with a significant portion attributed to non-recurring gains[73]. - The fair value changes from trading financial assets and derivatives generated a profit of 176,366,249.20 CNY, classified as regular operating income due to the nature of the business[73]. - The company reported a total profit for the period of CNY 487,312,008.57, down 88.76% year-on-year[114]. - The investment income decreased by 89.57% to ¥20,089,978.44, primarily due to the disposal of equity in joint ventures in the same period last year[172]. - The gross margin for the bioproducts sector was 52.32%, down by 23.50% year-on-year[175]. Environmental and Regulatory Compliance - The company has been classified as a key environmental risk control unit due to hazardous waste generation exceeding 100 tons per year, leading to stricter waste management protocols[9]. - The company has not experienced any sudden environmental incidents during the reporting period, and conducted emergency drills for hazardous chemicals in June 2023[10]. - The company has received multiple environmental impact assessment approvals for various projects, indicating ongoing expansion and compliance with regulatory requirements[30]. - The company’s major pollutants include noise, waste gas, wastewater, and solid waste, with noise levels recorded at 58.7 dB(A), below the standard limit of 60 dB(A)[32]. Strategic Initiatives and Market Position - The company is adapting to new market operational rules due to ongoing reforms in the pharmaceutical and healthcare sectors, particularly in the in vitro diagnostics industry[5]. - The company is exploring market expansion opportunities, particularly in the healthcare diagnostics sector, to leverage growth potential[75]. - The company is committed to enhancing its operational efficiency and profitability through strategic investments and product innovation[75]. - The company is actively pursuing strategic partnerships and potential acquisitions to bolster its capabilities and market reach[77]. - The company is focused on expanding its market presence through the introduction of new products and technologies, particularly in the field of infectious disease testing[77]. - The company has established a multi-level incentive mechanism to improve human resource management and enhance operational efficiency[145]. - The company has implemented a comprehensive performance and incentive management system to enhance employee morale and efficiency[119]. Research and Development - The company is investing in research and development to enhance its product offerings, particularly in the areas of genetic testing and infectious disease diagnostics[77]. - The company continues to invest in R&D, enhancing its core competitiveness through an efficient and open research platform[116]. - The company is focusing on research innovation and the application of new technologies and products to drive revenue and profit growth in the biopharmaceutical sector[4]. - The company emphasizes the importance of continuous technological innovation and new product launches in the IVD industry to maintain competitive advantage[192]. Product Portfolio and Market Trends - The company has a diverse product line including various nucleic acid testing kits for viruses such as COVID-19, hepatitis B, and influenza, indicating a strong focus on healthcare products[75]. - The company has launched a series of diagnostic products covering tumor markers, hepatitis, hormones, prenatal screening, and more, with multiple product approvals in 2022[1]. - The company has developed multiple advanced diagnostic technology platforms, including nucleic acid and immunological diagnostic technology[150]. - The company has over 500 registered medical device certificates and more than 100 invention patents, indicating a strong product reserve[151]. - The global IVD market is experiencing rapid growth, becoming a market worth hundreds of billions, with expectations for continued expansion due to new technologies and products[83]. - The domestic IVD product industry is rapidly developing, with accelerated innovation across various technology platforms and an increasing number of application products[85]. - The company has established itself as a leader in the molecular diagnostics industry, with prominent brands such as "Da An Gene" and "Da Rui Bio" leading the market[88]. Financial Management and Corporate Governance - The company has not undergone any bankruptcy reorganization during the reporting period[35]. - The company has not reported any changes in its board of directors or senior management during the reporting period[28]. - The company plans to not distribute cash dividends or issue bonus shares for the reporting period[19]. - The company has not reported any significant losses from entrusted loans or investment properties, indicating stable financial management[73]. - The company has not utilized any raised funds during the reporting period[187]. - There were no significant asset sales during the reporting period[188]. - The company does not engage in derivative investments during the reporting period[186].

广州达安基因股份有限公司（以下简称"公司"）全资孙公司达安国际集团 有限公司（以下简称"达安国际"）近日收到其参股公司云康集团有限公司（以 下简称"云康集团"）的现金分红款，具体情况如下： 根据云康集团于 2023 年 6 月 28 日召开的股东周年大会，其审议通过了"宣 派截至 2022 年 12 月 31 日止年度之末期股息每股 0.22 港元，自本公司股份溢价 账拨付"的议案。公司全资孙公司达安国际持有云康集团股份 209,783,000 股， 本次现金分红金额为 46,152,260.00 港元。 近日，公司全资孙公司达安国际已收到上述现金分红款 46,152,260.00 港元。 公司对云康集团的长期股权投资按权益法核算，该笔分红款对公司 2023 年度合 并报表净利润无影响。 证券代码：002030 证券简称：达安基因 公告编号：2023-033 广州达安基因股份有限公司 关于全资孙公司收到现金分红款的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 8 月 28 日 特此公告。 广州达安基因股份有限公司 董 事 会 ...

附件： + 热烈欢迎中情压势、 8月1日 38:本 475455 [19] 101 注：图右一为公司董事会秘书张斌与调研人员合影留念。 ...

证券代码：002030 证券简称：达安基因 编号：2023005 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他（） 中信证券 张秋尘 贾皓阳 参与单位名称及 毅恒资本 郭远山 郑达鑫 人员姓名 时间 2023-07-21（下午 15:30-下午 17:00） 地点 广州市高新技术开发区科学城香山路 19 号（公司总部） 上市公司接待人 员姓名 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：站着企业长期发展的视角来看，公司未来五年的规划 是什么？ 答：公司主要发展方向就是从分子诊断领域走向IVD全诊断领 投资者关系活动 域。未来公司将全面落实进入IVD全领域的发展策略，聚焦于 主要内容介绍 诊断技术和产品的临床、公共卫生、检验检疫、生命健康相关 领域等全场景应用，继续做大做强PCR及分子诊断技术、产品 和市场领域，积极发展免疫、生化、分析仪器等全诊断技术平 台、产品和市场领域。 问题二：达安所具备的和其他企业的不同的独特点是什么？是 广州达安基因股份有 ...

附件： 热烈欢迎机构投资者 在临达安装 因识别 重庆有县 注：前排左七为公司董事会秘书张斌与调研人员合影留念。 ...

Group 1: Financial Performance - The company's accounts receivable for 2022 was approximately 4 billion, with Q1 2023 around 3.5 billion, indicating a good collection progress [2] - In 2021, the company invested 600 million in R&D, which increased to 1.1 billion in 2022 [2] - The company distributed over 2.4 billion in cash dividends to investors this year [2] Group 2: Business Strategy and Development - The company plans to expand its product lines into respiratory pathogens, gastrointestinal pathogens, reproductive health, and personalized medicine [2] - The company has enhanced its production capacity significantly, with daily output from PCR and POCT production lines increased compared to previous years [3] - The company employs a flexible production model based on market demand, reducing the risk of overcapacity [3] Group 3: Market Expansion and Innovation - The company aims to expand into overseas markets, focusing on regions with favorable economic conditions and open policies [3] - The company has a comprehensive production model, manufacturing raw materials, reagents, and equipment in-house [4] - The company emphasizes technological innovation and product development as key factors for success in the IVD industry [4] Group 4: Corporate Culture and Future Plans - The company's culture is rooted in "shared growth value," emphasizing technological innovation and scientific spirit [4] - The company plans to continue its strategy of "main business development + industrial incubation," focusing on biomedicine and health [4]

Group 1: Financial Performance - In 2022, the company's total revenue was approximately 12 billion CNY, with over 8 billion CNY from COVID-19 testing kits and around 3 billion CNY from other routine testing kits [1] - The sales volume of routine testing products in Q1 2023 remained stable compared to the same period in 2019, despite a significant increase in shipment volume [1] - The price of some testing kits has decreased by over 30% in the past two years, impacting revenue [1] Group 2: Strategic Decisions - The company issued a price adjustment notice to respond to national policies aimed at making healthcare more affordable and accessible [2] - The decision to lower prices is also based on the company's ability to control and reduce production costs through scaled manufacturing [2] - The company has been preparing to expand its product range into the IVD (In Vitro Diagnostics) field for several years, leveraging its established subsidiaries [2] Group 3: Expansion Projects - The company is currently working on an expansion project in the Knowledge City, focusing on automated production lines for consumables and high-end IVD equipment [2] - The expansion project is aimed at enhancing the company's research and development capabilities for biochemical diagnostic reagents [2] Group 4: Profitability Metrics - The gross profit margin in Q1 2023 was better than in 2019, attributed to a more efficient operational structure and economies of scale in production [3]

附件： 普资质 国家专利 R DAAN GENE Artificate of Honor National Patents a 注：图左二为公司董事会秘书张斌与国开证券仇艳、国开证券王雯及国开证券梅凯充合影 留念。 ...